Common Stock, $0.0001 par value per share
- Symbol
- ASRT
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Historical · closed Jun 16, 2026
Current Report · Items 7.01, 9.01 · 8-K
Item 7.01. Regulation FD Disclosure. On May 8, 2026, Assertio Holdings, Inc. (the “Company”) issued a press release (the “Press Release”) announcing that on May 7, 2026, in connection with the previously announced entry into an Amended and Restated Agreement and Plan of Merger, dated as of May 1, 2026 (the “Merger Agreement”), by and among the Company, Garda Therapeutics, Inc., a Delaware corporat…
Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products primarily in the oncology market. To learn more about Assertio, visit www.assertiotx.com.
ASSERTIO HOLDINGS, INC. · 8-K · Filed 2026-05-08
EX-99.1 2 tm2611405d24_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press Release Assertio and Garda Mutually Agree to Delay Launch of Tender Offer LAKE FOREST, IL - May 8, 2026 - Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”) to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio to May 14, 2026. As previously announced on May 4, 2026, Assertio has entered into an amended and restated merger agreement (the “Garda Agreement”) to be acquired by Garda for $21.80 per share in cash, or total cash consideration of $153.2 million. The Company expects to file a Schedule 14D-9 in connection with the tender offer on May 14, 2026. In addition, Assertio will delay the launch of the previously announced tender offer for all outstanding Convertible Senior Notes until May 14, 2026. About Assertio Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products primarily in the oncology …
Open exhibit ↗